Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
23 pending office actions • 11 art units • 21 examiners • 0 of 23 (0%) have an AI response strategy ready • 20 patents granted in the last 365 days
Fred Hutchinson Cancer Research Center maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area, currently navigating 23 pending office actions. These actions are spread across 21 distinct examiners, reflecting a wide-reaching prosecution strategy that engages many different individuals at the patent office. The technical breadth of the portfolio is further evidenced by its presence in 11 distinct art units, which is a significant distribution for a biotechnology-focused entity.
PARISI, JESSICA DANIELLE is the busiest examiner for the organization, currently managing 2 pending office actions. While the portfolio involves 21 distinct examiners, the concentration of 2 pending office actions with PARISI, JESSICA DANIELLE represents a specific point of focus within the larger total of 23 pending office actions. The management of 11 distinct art units suggests that the center's innovations cover a variety of specialized biological and pharmaceutical disciplines. This complexity requires careful attention to the distinct examination styles across the 21 examiners currently reviewing the center's applications.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 5 (22%) |
| §103 only | 1 (4%) |
| §102 only | 1 (4%) |
| §112 only | 4 (17%) |
| Double-patenting only | 1 (4%) |
| Double-patenting + other | 6 (26%) |
| Multi-statute (no §101) | 5 (22%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PARISI, JESSICA DANIELLE | 2 | 75.8% | +32.3% |
| ZHANG, KAIJIANG | 2 | 77.1% | +34.4% |
| COHEN, MICHAEL P | 1 | 58.7% | +27.5% |
| YOO, SUN JAE | 1 | 71.1% | +0.3% |
| PYLA, EVELYN Y | 1 | 55.7% | +47.1% |
| SZPERKA, MICHAEL EDWARD | 1 | 62.9% | +36.8% |
| KONOPKA, CATHERINE ANNE | 1 | 58.1% | +65.0% |
| REDDIG, PETER J | 1 | 57.9% | +40.2% |
| CORNELIUS, CLAIRE ADRIENNE | 1 | 66.7% | +0.0% |
| JOHANSEN, PETER N. | 1 | 59.3% | +24.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18458108 | EPSTEIN BARR VIRUS VACCINES | WANG, RUIXUE | 49d overdue |
| 18500706 | COMBINATION THERAPIES FOR TREATMENT OF BCMA-RELATED CANCERS AND AUTOIMMUNE DISORDERS | REDDIG, PETER J | 5d |
| 17412105 | COMPOSITIONS AND METHODS FOR ACCURATELY IDENTIFYING MUTATIONS | ZHANG, KAIJIANG | 65d |
| 18820648 | COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTION | PYLA, EVELYN Y | — |
| 18707096 | T CELL IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCIES HAVING AN SF3B1 MUTATION | SZPERKA, MICHAEL EDWARD | — |
| 18576216 | METHOD FOR ANALYZING THE ABILITY OF TARGET NUCLEIC ACID SEQUENCES TO IMPACT GENE EXPRESSION | PARISI, JESSICA DANIELLE | — |
| 18557406 | MOLECULAR SIGNATURES OF LONG-TERM COVID-19 AND TREATMENT THEREOF | CORNELIUS, CLAIRE ADRIENNE | — |
| 18251871 | THERAPEUTIC TARGETING OF MESOTHELIN IN ACUTE MYELOID LEUKEMIA WITH CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY | HOWARD, ZACHARY C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18500706 | COMBINATION THERAPIES FOR TREATMENT OF BCMA-RELATED CANCERS AND AUTOIMMUNE DISORDERS | REDDIG, PETER J | 5d |
| 17464341 | COMPOSITIONS AND METHODS FOR ACCURATELY IDENTIFYING MUTATIONS | ZHANG, KAIJIANG | 65d |
| 17412105 | COMPOSITIONS AND METHODS FOR ACCURATELY IDENTIFYING MUTATIONS | ZHANG, KAIJIANG | 65d |
| 19008094 | HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY | COHEN, MICHAEL P | — |
| 17029756 | CELL POPULATION ANALYSIS USING SINGLE NUCLEOTIDE POLYMORPHISMS FROM SINGLE CELL TRANSCRIPTOMES | PARISI, JESSICA DANIELLE | — |
| 18820648 | COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTION | PYLA, EVELYN Y | — |
| 18707096 | T CELL IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCIES HAVING AN SF3B1 MUTATION | SZPERKA, MICHAEL EDWARD | — |
| 18412351 | COMPOSITIONS AND METHODS TO PROGRAM THERAPEUTIC CELLS USING TARGETED NUCLEIC ACID NANOCARRIER | KONOPKA, CATHERINE ANNE | — |
| Art Unit | Apps |
|---|---|
| 1684 | 3 |
| 1658 | 3 |
| 1641 | 3 |
| 1672 | 2 |
| 1621 | 1 |
| 1646 | 1 |
| 1638 | 1 |
| 1642 | 1 |
| 1674 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19008094 | HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY | COHEN, MICHAEL P | — | §102§103§112DP | Non-Final OA | — | Pending | Jan 02, 2025 |
| 18797649 | COMPOSITIONS, KITS, AND METHODS TO INDUCE ACQUIRED CYTORESISTANCE USING STRESS PROTEIN INDUCERS | YOO, SUN JAE | 1621 | DP | Non-Final OA | — | Pending | Aug 08, 2024 |
| 17029756 | CELL POPULATION ANALYSIS USING SINGLE NUCLEOTIDE POLYMORPHISMS FROM SINGLE CELL TRANSCRIPTOMES | PARISI, JESSICA DANIELLE | 1684 | §103 | Final Rejection | — | Pending | Sep 23, 2020 |
| 18820648 | COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTION | PYLA, EVELYN Y | — | §103§112 | Non-Final OA | — | Pending | Aug 30, 2024 |
| 18707096 | T CELL IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCIES HAVING AN SF3B1 MUTATION | SZPERKA, MICHAEL EDWARD | — | §101§102§112 | Non-Final OA | — | Pending | May 02, 2024 |
| 18412351 | COMPOSITIONS AND METHODS TO PROGRAM THERAPEUTIC CELLS USING TARGETED NUCLEIC ACID NANOCARRIER | KONOPKA, CATHERINE ANNE | — | §112DP | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18576216 | METHOD FOR ANALYZING THE ABILITY OF TARGET NUCLEIC ACID SEQUENCES TO IMPACT GENE EXPRESSION | PARISI, JESSICA DANIELLE | — | §101§103§112 | Non-Final OA | — | Pending | Jan 03, 2024 |
| 18500706 | COMBINATION THERAPIES FOR TREATMENT OF BCMA-RELATED CANCERS AND AUTOIMMUNE DISORDERS | REDDIG, PETER J | 1646 | §101§102§103§112Other | Non-Final OA | 5d | Pending | Nov 02, 2023 |
| 18557406 | MOLECULAR SIGNATURES OF LONG-TERM COVID-19 AND TREATMENT THEREOF | CORNELIUS, CLAIRE ADRIENNE | 1672 | §101§103§112 | Non-Final OA | — | Pending | Oct 26, 2023 |
| 18288420 | Mesothelin-specific T cell Receptors and Methods of Using Same | JOHANSEN, PETER N. | 1658 | §112 | Non-Final OA | — | Pending | Oct 26, 2023 |
| 18491703 | ANTI-FOLATE RECEPTOR CONJUGATE THERAPY FOR CANCER TREATMENT | HADDAD, MAHER M | 1641 | §102§103§112DP | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18458108 | EPSTEIN BARR VIRUS VACCINES | WANG, RUIXUE | 1672 | §103§112 | Non-Final OA | 49d overdue | Pending | Aug 29, 2023 |
| 18456339 | DELTA-LIKE NON-CANONICAL NOTCH LIGAND 1 ACTIVITY MODULATORS AND USES THEREOF | KOMATSU, LI N | 1658 | §112 | Non-Final OA | — | Pending | Aug 25, 2023 |
| 18262674 | TREATMENT FOR HSV-1 USING A MEGANUCLEASE | ROGERS, ERIC JASON | 1638 | §102§103§112DP | Non-Final OA | — | Pending | Jul 24, 2023 |
| 18350637 | IGM-MULTIMERIZED SINGLE-DOMAIN ANTIBODIES THAT BIND ROR1 | PRIEST, JESSICA MARIE | 1642 | §112DP | Non-Final OA | — | Pending | Jul 11, 2023 |
| 18251871 | THERAPEUTIC TARGETING OF MESOTHELIN IN ACUTE MYELOID LEUKEMIA WITH CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY | HOWARD, ZACHARY C | 1674 | §103§112 | Final Rejection | — | Pending | May 04, 2023 |
| 18310649 | KSHV ONCOPROTEIN ANTIGENS AND EPITOPES FOR EXPANDING ANTIGEN-SPECIFIC T CELLS | ROONEY, NORA MAUREEN | 1641 | §112 | Final Rejection | 42d | Pending | May 02, 2023 |
| 18044289 | IMPROVED HIGH EFFICIENCY TARGETED IN SITU GENOME-WIDE PROFILING | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §103§112 | Final Rejection | — | Pending | Mar 07, 2023 |
| 18173485 | METHODS FOR ENHANCING ANTI-TUMOR ACTIVITY OF EXHAUSTED T CELLS | NGUYEN, QUANG | 1631 | §112 | Final Rejection | 2d overdue | Pending | Feb 23, 2023 |
| 17464341 | COMPOSITIONS AND METHODS FOR ACCURATELY IDENTIFYING MUTATIONS | ZHANG, KAIJIANG | 1684 | §102 | Non-Final OA | 65d | Pending | Sep 01, 2021 |
| 17412105 | COMPOSITIONS AND METHODS FOR ACCURATELY IDENTIFYING MUTATIONS | ZHANG, KAIJIANG | 1684 | §101§102§112 | Non-Final OA | 65d | Pending | Aug 25, 2021 |
| 17312703 | TRANSFERRIN RECEPTOR TARGETING PEPTIDES | FISCHER, JOSEPH | 1658 | §112DP | Final Rejection | — | Pending | Jun 10, 2021 |
| 17272117 | METHODS AND COMPOSITIONS FOR ADOPTIVE T CELL THERAPY INCORPORATING INDUCED NOTCH SIGNALING | DIBRINO, MARIANNE | 1641 | §103§112 | Non-Final OA | — | Pending | Feb 26, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial